Nexgel

NexGel, Inc. engages in the manufacture of polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The company was founded on January 13, 2009 and is headquartered in Langhorne, PA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nexgel reports record revenue in Q2 2024, anticipates strong growth

Nexgel's Q2 2024 performance reflects robust revenue growth driven by strategic acquisitions and expansion efforts.
Despite short-term challenges in capacity expansion, the company's financial outlook remains positive with strong revenue guidance.
Opportunities from new partnerships and product launches position Nexgel for continued growth and market success.

Nexgel reports record Q3 earnings, eyes growth through strategic initiatives

Nexgel's Q3 2024 showcased robust financial performance with record revenue and improved margins.
Strategic acquisitions, partnerships, and growth initiatives position Nexgel for continued success.
While challenges like sustaining growth and managing costs exist, opportunities for expansion and profitability are promising.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NexGel, Inc. engages in the manufacture of aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The company was founded on January 13, 2009 and is headquartered in Langhorne, PA.

NEXGEL, Inc. (NASDAQ:NXGL ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Maria Honeycutt - Account Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer Adam Drapczuk - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Michael Gustitus - One Pride George Marema - Pareto Adventures Operator Good afternoon, ladies and gentlemen. Welcome to NEXGEL's Third Quarter 2024 Earnings Conference Call.

NEXGEL, Inc. (NXGL) Q3 2024 Earnings Call Transcript

Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing

NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially

LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 727,272 of its shares of common stock and the issuance of warrants to purchase up to an aggregate of 363,636 shares of common stock for a combined offering purchase price of $2.75 per share of common stock in a registered direct offering. The warrants will have an exercise price of $4.25 per share and be exercisable immediately upon issuance and have a term of five years from the date of issuance.

NEXGEL Announces $2,000,000 Registered Direct Offering

LANGHORNE, Pa., Oct. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, is scheduled to participate in the following October 2024 investor conferences.

NEXGEL to Participate in Upcoming October Investor Conferences

LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board.

NEXGEL Appoints Kip Crecca to its Scientific Advisory Board

NEXGEL, Inc. (NASDAQ:NXGL ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer, President and Director Adam Drapczuk - Chief Financial Officer Conference Call Participants William Odenthal - COVA Capital Partners Eric Ramos - Titan Capital Management Operator Good afternoon. I will be your conference operator today.

NEXGEL, Inc. (NXGL) Q2 2024 Earnings Call Transcript

LANGHORNE, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record second quarter 2024 revenue of $1.44 million and is reiterating revenue guidance for the 2024 third and fourth quarter of $2.2 million and $2.6 million, respectively.

NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.

NEXGEL to Report Second Quarter 2024 Financial Results on August 14th

The 30-patient study is designed to measure the efficacy of applying NEXGEL's hydrogel during laser hair removal in eliminating harmful particles or plume during treatments

NEXGEL and Innovative Optics US Initiate Institutional Review Board (IRB) Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal

LANGHORNE, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced preliminary, unaudited revenue for the second quarter of 2024 and has provided revenue guidance for the third and fourth quarter of 2024.

NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively

LANGHORNE, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the first product to be distributed under its recently formed partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health. Histasolv®, sold as DAOSIN® in Europe, is Europe's number one selling Diamine Oxidase (‘DAO') enzyme supplement generating well over $10 million in annualized revenue to treat histamine food intolerance, which can cause migraines and headaches, gut issues, and skin conditions. Headquartered in Germany, STADA is one of the fastest growing top ten companies in consumer healthcare and the fourth largest manufacturer in this segment in Europe.

NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America

Acquisition further expands NEXGEL Health, Wellness, and Beauty consumer product portfolio Silly George is on a revenue run rate of approximately $2 million LANGHORNE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the acquisition of Silly George , an international beauty company with specialty in eye and eyelash consumer products and a revenue run rate of approximately $2 million.

NEXGEL Acquires International Beauty Brand, Silly George

NEXGEL, Inc. (NASDAQ:NXGL ) Q1 2024 Results Conference Call May 13, 2024 4:30 PM ET Company Participants Valter Pinto - Managing Director, KCSA Strategic Communications Adam Levy - Chief Executive Officer Adam Drapczuk - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Good afternoon, everyone. My name is Beau, and I will be your conference operator today.

NEXGEL, Inc. (NXGL) Q1 2024 Earnings Call Transcript

NEXGEL, Inc. (NXGL) Q4 2023 Earnings Call Transcript

LANGHORNE, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the fourth quarter and full year ended December 31, 2023.

NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year

LANGHORNE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced rescheduling its financial results conference call for the fourth quarter and full year 2023 to Monday, April 1st at 8:30 a.m. ET. The Company intends to file its Form 10-K with the SEC and issue a press release prior to the start of the call.

NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday

NEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28th

LANGHORNE, Pa., March 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, is scheduled to present at the iAccess Alpha Best Ideas Spring Virtual Conference taking place March 12th and 13th.

NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th

LANGHORNE, Pa., Jan. 09, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced a 12,000 square foot expansion of its CG Converting and Packaging facility in Granbury, Texas. The expansion will support the expected growth in product demand from its new strategic partnerships as well as continued growth of NEXGEL's own branded products.

NEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024

LANGHORNE, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced a partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health, to distribute and commercialize consumer health OTC products in North America in 2024.

NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America

NEXGEL, Inc. (NASDAQ:NXGL ) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants Valter Pinto - MD, KCSA Strategic Communications Adam Levy - CEO Adam Drapczuk - CFO Conference Call Participants Naz Rahman - Maxim Group Operator Good afternoon. I will be your conference operator today.

NEXGEL, Inc. (NXGL) Q3 2023 Earnings Call Transcript

Rocket Lab USA

Sarepta Therapeutics

The recent surge in official interest rates, the most substantial in 40 years, is anticipated to impact aggregate demand significantly. This could potentially result in a GDP reduction of approximately 4 percent for the current year, followed by an additional 1% decrease in 2024.

3 Stocks You'll Regret Not Buying Soon: November 2023

Gross profit margin improved sequentially to 28.2% in Q3 as compared to 15.0% in Q2 LANGHORNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the third quarter ended September 30, 2023.

NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year

AbbVie

NEXGEL (NASDAQ:NXGL) announced that its CG Converting and Packaging subsidiary has executed a supply agreement with biopharmaceutical giant AbbVie Inc to be a supplier of gel pads to be used with AbbVie's Rapid Acoustic Pulse device being investigated for improvement in the appearance of cellulite.   The provider of high-water-content hydrogel products said by leveraging its proprietary hydrogel technology, the gel pads will be an important component of the body contouring device.

NEXGEL announces supply agreement with AbbVie

LANGHORNE, Pa., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, CEO, will participate in the LD Micro Main Event XVI being held on October 3rd – 5th in Los Angeles.

News for Nexgel Stock (NXGL)